Bringing the heavy: Carbon ion therapy in the radiobiological and clinical context

Radiation Oncology

Volumn 9, Issue 1, 2014, Pages

  Schlaff, Cody D ^a   Krauze, Andra ^a   Belard, Arnaud ^b   O'Connell, John J ^b   Camphausen, Kevin A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

Cancer stem cells; Carbon ions; Hypoxia; Radiobiology; Radiotherapy; Tumor metabolism; Tumor microenvironment; ratio

Indexed keywords

CARBON; DNA; GLUCOSE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IRON; LACTIC ACID; SURVIVIN; VASCULOTROPIN; HEAVY ION; OXYGEN;

ALPHA RADIATION; BETA RADIATION; CANCER CELL DESTRUCTION; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CELL METABOLISM; DNA DAMAGE; G2 PHASE CELL CYCLE CHECKPOINT; GLIOMA; GLUCOSE METABOLISM; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPOXIA; INTENSITY MODULATED RADIATION THERAPY; INTRACRANIAL TUMOR; ION THERAPY; IRON METABOLISM; LINEAR ENERGY TRANSFER; LIVER CELL CARCINOMA; OXYGEN ENHANCEMENT RATIO; PATHOLOGICAL ANATOMY; PHOTON THERAPY; PROTEIN EXPRESSION; PROTON THERAPY; RADIATION DOSE FRACTIONATION; RADIOBIOLOGY; RADIOSENSITIVITY; RELATIVE BIOLOGIC EFFECTIVENESS; REVIEW; THORAX TUMOR; TREATMENT FAILURE; TUMOR MICROENVIRONMENT; UPREGULATION; UTERINE CERVIX CANCER; ANOXIA; CELL CYCLE; CELL PROLIFERATION; CHEMISTRY; CLINICAL TRIAL (TOPIC); CYTOLOGY; METABOLISM; NEOPLASMS; PROCEDURES; RADIOTHERAPY; STEM CELL;

ANOXIA; CARBON; CELL CYCLE; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; GLUCOSE; HEAVY ION RADIOTHERAPY; HEAVY IONS; HUMANS; LINEAR ENERGY TRANSFER; NEOPLASMS; NEOPLASTIC STEM CELLS; OXYGEN; RADIOTHERAPY; STEM CELLS; TUMOR MICROENVIRONMENT;

EID: 84899535810     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-9-88     Document Type: Review

References (172)

1. Slater J. From X-Rays to Ion Beams: A Short History of Radiation Therapy. Ion Beam Therapy: Fundamentals, Technology, Clinical Applications 2012, 320:3-16.
2. Hadron Therapy Patient Statistics (data recieved from centers per end of March 2013) http://ptcog.web.psi.ch/Archive/pat_statistics/Patientstatistics-updateMar2013.pdf.
3. Alonso JR. Accelerators for America's Future Workshop: Medicine and Biology. Health Phys 2012, 103:667-673. 10.1097/HP.0b013e318260650b, 23032897.
4. Peeters A, Grutters JP, Pijls-Johannesma M, Reimoser S, De Ruysscher D, Severens JL, Joore MA, Lambin P. How costly is particle therapy? Cost analysis of external beam radiotherapy with carbon-ions, protons and photons. Radiother Oncol 2010, 95:45-53. 10.1016/j.radonc.2009.12.002, 20106540.
5. Pijls-Johannesma M, Pommier P, Lievens Y. Cost-effectiveness of particle therapy: current evidence and future needs. Radiother Oncol 2008, 89:127-134. 10.1016/j.radonc.2008.07.015, 18707784.
6. Lievens Y, Pijls-Johannesma M. Health economic controversy and cost-effectiveness of proton therapy. Semin Radiat Oncol 2013, 23:134-141. 10.1016/j.semradonc.2012.11.005, 23473691.
7. Grutters JP, Pijls-Johannesma M, Ruysscher DD, Peeters A, Reimoser S, Severens JL, Lambin P, Joore MA. The cost-effectiveness of particle therapy in non-small cell lung cancer: exploring decision uncertainty and areas for future research. Cancer Treat Rev 2010, 36:468-476. 10.1016/j.ctrv.2010.02.018, 20303217.
8. Workshop on Ion Beam Therapy. Joint DOE-NCI Workshop on Ion Beam Therapy 2013, Bethesda, MD, http://science.energy.gov/~/media/hep/pdf/accelerator-rd-stewardship/Workshop_on_Ioxn_Beam_Therapy_Report_Final_R1.pdf.
9. Fokas E, Kraft G, An H, Engenhart-Cabillic R. Ion beam radiobiology and cancer: time to update ourselves. Biochimica et biophysica acta 2009, 1796:216-229.
10. Hall EJ, Giaccia AJ. Radiobiology for the radiologist 2012, Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins, 7.
11. Lee SP, Leu MY, Smathers JB, McBride WH, Parker RG, Withers HR. Biologically effective dose distribution based on the linear quadratic model and its clinical relevance. Int J Radiat Oncol Biol Phys 1995, 33:375-389. 10.1016/0360-3016(95)00162-R, 7673025.
12. Withers HR, Thames HD, Peters LJ. A new isoeffect curve for change in dose per fraction. Radiother Oncol 1983, 1:187-191. 10.1016/S0167-8140(83)80021-8, 6680223.
13. Fowler JF. Review: total doses in fractionated radiotherapy-implications of new radiobiological data. Int J Radiat Biol Relat Stud Phys Chem Med 1984, 46:103-120. 10.1080/09553008414551181, 6381354.
14. Williams MV, Denekamp J, Fowler JF. A review of alpha/beta ratios for experimental tumors: implications for clinical studies of altered fractionation. Int J Radiat Oncol Biol Phys 1985, 11:87-96. 10.1016/0360-3016(85)90366-9, 3881377.
15. Peschke P, Karger CP, Scholz M, Debus J, Huber PE. Relative biological effectiveness of carbon ions for local tumor control of a radioresistant prostate carcinoma in the rat. Int J Radiat Oncol Biol Phys 2011, 79:239-246. 10.1016/j.ijrobp.2010.07.1976, 20934276.
16. Weyrather WK, Ritter S, Scholz M, Kraft G. RBE for carbon track-segment irradiation in cell lines of differing repair capacity. Int J Radiat Biol 1999, 75:1357-1364. 10.1080/095530099139232, 10597910.
17. Deacon J, Peckham MJ, Steel GG. The radioresponsiveness of human tumours and the initial slope of the cell survival curve. Radiother Oncol 1984, 2:317-323. 10.1016/S0167-8140(84)80074-2, 6395213.
18. Saigal K, Weed DT, Reis IM, Markoe AM, Wolfson AH, Nguyen-Sperry J. Mucosal melanomas of the head and neck: the role of postoperative radiation therapy. ISRN Oncol 2012, 2012:785131. 3345242, 22577582.
19. Yanagi T, Mizoe JE, Hasegawa A, Takagi R, Bessho H, Onda T, Kamada T, Okamoto Y, Tsujii H. Mucosal malignant melanoma of the head and neck treated by carbon ion radiotherapy. Int J Radiat Oncol Biol Phys 2009, 74:15-20. 10.1016/j.ijrobp.2008.07.056, 19046826.
20. Jingu K, Tsujii H, Mizoe JE, Hasegawa A, Bessho H, Takagi R, Morikawa T, Tonogi M, Tsuji H, Kamada T, Yamada S. Carbon ion radiation therapy improves the prognosis of unresectable adult bone and soft-tissue sarcoma of the head and neck. Int J Radiat Oncol Biol Phys 2012, 82:2125-2131. 10.1016/j.ijrobp.2010.08.043, 21745719.
21. Tsujii H, Kamada T. A review of update clinical results of carbon ion radiotherapy. Japanese journal of clinical oncology 2012, 42:670-685. 10.1093/jjco/hys104, 3405871, 22798685.
22. Shipley WU, Verhey LJ, Munzenrider JE, Suit HD, Urie MM, McManus PL, Young RH, Shipley JW, Zietman AL, Biggs PJ. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys 1995, 32:3-12. 10.1016/0360-3016(95)00063-5, 7721636.
23. Zietman AL, DeSilvio ML, Slater JD, Rossi CJ, Miller DW, Adams JA, Shipley WU. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005, 294:1233-1239. 10.1001/jama.294.10.1233, 16160131.
24. Michalski JM, Bae K, Roach M, Markoe AM, Sandler HM, Ryu J, Parliament MB, Straube W, Valicenti RK, Cox JD. Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study. Int J Radiat Oncol Biol Phys 2010, 76:14-22. 10.1016/j.ijrobp.2009.01.062, 2795116, 19577865.
25. Nikoghosyan AV, Karapanagiotou-Schenkel I, Munter MW, Jensen AD, Combs SE, Debus J. Randomised trial of proton vs. carbon ion radiation therapy in patients with chordoma of the skull base, clinical phase III study HIT-1-Study. BMC Cancer 2010, 10:607. 10.1186/1471-2407-10-607, 2988755, 21054824.
26. Henderson FC, McCool K, Seigle J, Jean W, Harter W, Gagnon GJ. Treatment of chordomas with CyberKnife: georgetown university experience and treatment recommendations. Neurosurgery 2009, 64:A44-53. 10.1227/01.NEU.0000341166.09107.47, 19165073.
27. Friedrich T, Weyrather W, Elsasser T, Durante M, Scholz M. Accuracy of RBE: experimental and theoretical considerations. Radiat Environ Biophys 2010, 49:345-349. 10.1007/s00411-010-0298-9, 20556619.
28. Gray L, Conger A, Ebert M, Hornsey S, Scott O. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. The British journal of radiology 1953, 26:638-648. 10.1259/0007-1285-26-312-638, 13106296.
29. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996, 41:31-39. 10.1016/S0167-8140(96)91811-3, 8961365.
30. Hockel M, Schlenger K, Mitze M, Schaffer U, Vaupel P. Hypoxia and Radiation Response in Human Tumors. Semin Radiat Oncol 1996, 6:3-9. 10.1016/S1053-4296(96)80031-2, 10717157.
31. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007, 26:225-239. 10.1007/s10555-007-9055-1, 17440684.
32. Schmid T, Dollinger G, Beisker W, Hable V, Greubel C, Auer S, Mittag A, Tarnok A, Friedl A, Molls M, Röper B. Differences in the kinetics of gamma-H2AX fluorescence decay after exposure to low and high LET radiation. International journal of radiation biology 2010, 86:682-691. 10.3109/09553001003734543, 20569192.
33. Tatiana W, Jan JW. Modelling of the oxygen enhancement ratio for ion beam radiation therapy. Physics in medicine and biology 2011, 56:3251-3268. 10.1088/0031-9155/56/11/006, 21540489.
34. Meesungnoen J, Jay-Gerin JP. High-LET ion radiolysis of water: oxygen production in tracks. Radiat Res 2009, 171:379-386. 10.1667/RR1468.1, 19267566.
35. Prise KM, Folkard M, Davies S, Michael BD. Measurement of DNA damage and cell killing in Chinese hamster V79 cells irradiated with aluminum characteristic ultrasoft X rays. Radiat Res 1989, 117:489-499. 10.2307/3577354, 2928471.
36. Ward JF. The complexity of DNA damage: relevance to biological consequences. Int J Radiat Biol 1994, 66:427-432. 10.1080/09553009414551401, 7983426.
37. Michael BD, Prise KM. A multiple-radical model for radiation action on DNA and the dependence of OER on LET. Int J Radiat Biol 1996, 69:351-358. 10.1080/095530096145913, 8613685.
38. Brown J, Wilson W. Exploiting tumour hypoxia in cancer treatment. Nature reviews Cancer 2004, 4:437-447. 10.1038/nrc1367, 15170446.
39. Wenzl T, Wilkens J. Theoretical analysis of the dose dependence of the oxygen enhancement ratio and its relevance for clinical applications. Radiation oncology (London, England) 2011, 6:171.
40. Meijer T, Kaanders J, Span P, Bussink J. Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. Clinical cancer research: an official journal of the American Association for Cancer Research 2012, 18:5585-5594. 10.1158/1078-0432.CCR-12-0858, 23071360.
41. Harada H. How can we overcome tumor hypoxia in radiation therapy?. Journal of radiation research 2011, 52:545-556. 10.1269/jrr.11056, 21952313.
42. Moeller BJ, Cao Y, Li CY, Dewhirst MW. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 2004, 5:429-441. 10.1016/S1535-6108(04)00115-1, 15144951.
43. Shi M, Guo XT, Shu MG, Li LW. Enhancing tumor radiosensitivity by intracellular delivery of survivin antagonists. Med Hypotheses 2007, 68:1056-1058. 10.1016/j.mehy.2006.09.048, 17107755.
44. Wei H, Wang C, Chen L. Proliferating cell nuclear antigen, survivin, and CD34 expressions in pancreatic cancer and their correlation with hypoxia-inducible factor 1alpha. Pancreas 2006, 32:159-163. 10.1097/01.mpa.0000202961.71600.9b, 16552335.
45. Li DW, Zhou L, Jin B, Xie J, Dong P. Expression and significance of hypoxia-inducible factor-1alpha and survivin in laryngeal carcinoma tissue and cells. Otolaryngol Head Neck Surg 2013, 148:75-81. 10.1177/0194599812464759, 23087365.
46. Shi M, Guo XT, Shu MG, Chen FL, Li LW. Cell-permeable hypoxia-inducible factor-1 (HIF-1) antagonists function as tumor radiosensitizers. Med Hypotheses 2007, 69:33-35. 10.1016/j.mehy.2006.10.062, 17280792.
47. Bache M, Kappler M, Said HM, Staab A, Vordermark D. Detection and specific targeting of hypoxic regions within solid tumors: current preclinical and clinical strategies. Curr Med Chem 2008, 15:322-338. 10.2174/092986708783497391, 18288988.
48. Rampling R, Cruickshank G, Lewis AD, Fitzsimmons SA, Workman P. Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys 1994, 29:427-431. 10.1016/0360-3016(94)90432-4, 8005794.
49. Collingridge DR, Piepmeier JM, Rockwell S, Knisely JP. Polarographic measurements of oxygen tension in human glioma and surrounding peritumoural brain tissue. Radiother Oncol 1999, 53:127-131. 10.1016/S0167-8140(99)00121-8, 10665789.
50. Kayama T, Yoshimoto T, Fujimoto S, Sakurai Y. Intratumoral oxygen pressure in malignant brain tumor. J Neurosurg 1991, 74:55-59. 10.3171/jns.1991.74.1.0055, 1984507.
51. Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, Becker A, Adam M, Molls M, Dunst J, Terris DJ, Overgaard J. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005, 77:18-24. 10.1016/j.radonc.2005.06.038, 16098619.
52. Harrison LB, Chadha M, Hill RJ, Hu K, Shasha D. Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist 2002, 7:492-508. 10.1634/theoncologist.7-6-492, 12490737.
53. Urtasun RC, Chapman JD, Raleigh JA, Franko AJ, Koch CJ. Binding of 3H-misonidazole to solid human tumors as a measure of tumor hypoxia. Int J Radiat Oncol Biol Phys 1986, 12:1263-1267. 10.1016/0360-3016(86)90273-7, 3017905.
54. Evans SM, Jenkins KW, Jenkins WT, Dilling T, Judy KD, Schrlau A, Judkins A, Hahn SM, Koch CJ. Imaging and analytical methods as applied to the evaluation of vasculature and hypoxia in human brain tumors. Radiat Res 2008, 170:677-690. 10.1667/RR1207.1, 2629387, 19138031.
55. Evans SM, Judy KD, Dunphy I, Jenkins WT, Hwang WT, Nelson PT, Lustig RA, Jenkins K, Magarelli DP, Hahn SM, Collins RA, Grady MS, Koch CJ. Hypoxia is important in the biology and aggression of human glial brain tumors. Clin Cancer Res 2004, 10:8177-8184. 10.1158/1078-0432.CCR-04-1081, 15623592.
56. Citrin D, Camphausen K, Curran W, Dicker A. Evaluation of novel agents as radiosensitizers from laboratory to clinic. ASCO Educational Book 2007, 4.
57. Stobbe CC, Park SJ, Chapman JD. The radiation hypersensitivity of cells at mitosis. Int J Radiat Biol 2002, 78:1149-1157. 10.1080/09553000210166570, 12556342.
58. Wang H, Wang X, Zhang P, Wang Y. The Ku-dependent non-homologous end-joining but not other repair pathway is inhibited by high linear energy transfer ionizing radiation. DNA Repair (Amst) 2008, 7:725-733. 10.1016/j.dnarep.2008.01.010, 18325854.
59. Tsuboi K, Moritake T, Tsuchida Y, Tokuuye K, Matsumura A, Ando K. Cell cycle checkpoint and apoptosis induction in glioblastoma cells and fibroblasts irradiated with carbon beam. J Radiat Res 2007, 48:317-325. 10.1269/jrr.06081, 17548940.
60. Marks LB, Dewhirst M. Accelerated repopulation: friend or foe? Exploiting changes in tumor growth characteristics to improve the "efficiency" of radiotherapy. Int J Radiat Oncol Biol Phys 1991, 21:1377-1383. 10.1016/0360-3016(91)90301-J, 1938539.
61. Arai T, Kuroishi T, Saito Y, Kurita Y, Naruke T, Kaneko M. Tumor doubling time and prognosis in lung cancer patients: evaluation from chest films and clinical follow-up study. Japanese Lung Cancer Screening Research Group. Jpn J Clin Oncol 1994, 24:199-204.
62. Pich A, Chiusa L, Navone R. Prognostic relevance of cell proliferation in head and neck tumors. Ann Oncol 2004, 15:1319-1329. 10.1093/annonc/mdh299, 15319236.
63. Nichols AC, Whelan F, Basmaji J, Dhaliwal S, Dowthwaite S, Chapeskie C, Read N, Palma DA, Fung K, Venkatesan V, Hammond JA, Franklin JH, Siddiqui I, Wehrli B, Kwan K, Koropatnick J, Mymryk JS, Barrett JW, Yoo J. Ki-67 expression predicts radiotherapy failure in early glottic cancer. J Otolaryngol Head Neck Surg 2012, 41:124-130.
64. Choi N, Baumann M, Flentjie M, Kellokumpu-Lehtinen P, Senan S, Zamboglou N, Kosmidis P. Predictive factors in radiotherapy for non-small cell lung cancer: present status. Lung Cancer 2001, 31:43-56. 10.1016/S0169-5002(00)00156-2, 11162866.
65. Fowler JF, Lindstrom MJ. Loss of local control with prolongation in radiotherapy. Int J Radiat Oncol Biol Phys 1992, 23:457-467. 10.1016/0360-3016(92)90768-D, 1534082.
66. Bonnet D, Dick J. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature medicine 1997, 3:730-737. 10.1038/nm0797-730, 9212098.
67. Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality?. Nat Med 2009, 15:1010-1012. 10.1038/nm0909-1010, 19734877.
68. Singh S, Clarke I, Terasaki M, Bonn V, Hawkins C, Squire J, Dirks P. Identification of a cancer stem cell in human brain tumors. Cancer research 2003, 63:5821-5828.
69. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 2007, 104:973-978. 10.1073/pnas.0610117104, 1783424, 17210912.
70. Li C, Lee CJ, Simeone DM. Identification of human pancreatic cancer stem cells. Methods Mol Biol 2009, 568:161-173. 10.1007/978-1-59745-280-9_10, 19582426.
71. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C, De Maria R. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008, 15:504-514. 10.1038/sj.cdd.4402283, 18049477.
72. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, Zhan Q, Jordan S, Duncan LM, Weishaupt C, Fuhlbrigge RC, Kupper TS, Sayegh MH, Frank MH. Identification of cells initiating human melanomas. Nature 2008, 451:345-349. 10.1038/nature06489, 3660705, 18202660.
73. Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A, Dewhirst M, Bigner D, Rich J. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760. 10.1038/nature05236, 17051156.
74. Blazek ER, Foutch JL, Maki G. Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133- cells, and the CD133+ sector is enlarged by hypoxia. Int J Radiat Oncol Biol Phys 2007, 67:1-5. 10.1016/j.ijrobp.2006.09.037, 17084552.
75. Heddleston JM, Hitomi M, Venere M, Flavahan WA, Yang K, Kim Y, Minhas S, Rich JN, Hjelmeland AB. Glioma stem cell maintenance: the role of the microenvironment. Curr Pharm Des 2011, 17:2386-2401. 10.2174/138161211797249260, 3615428, 21827414.
76. Masunaga S, Sakurai Y, Tanaka H, Hirayama R, Matsumoto Y, Uzawa A, Suzuki M, Kondo N, Narabayashi M, Maruhashi A, Ono K. Radiosensitivity of pimonidazole-unlabelled intratumour quiescent cell population to gamma-rays, accelerated carbon ion beams and boron neutron capture reaction. Br J Radiol 2013, 86:20120302. 3615400, 23255546.
77. Russell J, Wheldon TE, Stanton P. A radioresistant variant derived from a human neuroblastoma cell line is less prone to radiation-induced apoptosis. Cancer Res 1995, 55:4915-4921.
78. Robson T, Price ME, Moore ML, Joiner MC, McKelvey-Martin VJ, McKeown SR, Hirst DG. Increased repair and cell survival in cells treated with DIR1 antisense oligonucleotides: implications for induced radioresistance. Int J Radiat Biol 2000, 76:617-623. 10.1080/095530000138277, 10866283.
79. Gürsel D, Beyene R, Hofstetter C, Greenfield J, Souweidane M, Kaplitt M, Arango-Lievano M, Howard B, Boockvar J. Optimization of glioblastoma multiforme stem cell isolation, transfection, and transduction. Journal of neuro-oncology 2011, 104:509-522.
80. Gürsel D, Shin B, Burkhardt J-K, Kesavabhotla K, Schlaff C, Boockvar J. Glioblastoma Stem-Like Cells-Biology and Therapeutic Implications. Cancers 2011, 3:2655-2666. 10.3390/cancers3022655, 3142771,3142771, 21796273.
81. Diehn M, Cho R, Lobo N, Kalisky T, Dorie M, Kulp A, Qian D, Lam J, Ailles L, Wong M, Joshua B, Kaplan M, Wapnir I, Dirbas F, Somlo G, Garberoglio C, Paz B, Shen J, Lau S, Quake S, Brown J, Weissman I, Clarke M. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009, 458:780-783. 10.1038/nature07733, 2778612, 19194462.
82. Charles NA, Holland EC, Gilbertson R, Glass R, Kettenmann H. The brain tumor microenvironment. Glia 2012, 60:502-514. 10.1002/glia.21264, 22379614.
83. Cedervall J, Zhang Y, Ringvall M, Thulin A, Moustakas A, Jahnen-Dechent W, Siegbahn A, Olsson AK. HRG regulates tumor progression, epithelial to mesenchymal transition and metastasis via platelet-induced signaling in the pre-tumorigenic microenvironment. Angiogenesis 2013, 16(4):889-908. 10.1007/s10456-013-9363-8, 23793459.
84. Dellas K, Bache M, Pigorsch SU, Taubert H, Kappler M, Holzapfel D, Zorn E, Holzhausen HJ, Haensgen G. Prognostic impact of HIF-1alpha expression in patients with definitive radiotherapy for cervical cancer. Strahlenther Onkol 2008, 184:169-174.
85. Koukourakis MI, Giatromanolaki A, Danielidis V, Sivridis E. Hypoxia inducible factor (HIf1alpha and HIF2alpha) and carbonic anhydrase 9 (CA9) expression and response of head-neck cancer to hypofractionated and accelerated radiotherapy. Int J Radiat Biol 2008, 84:47-52. 10.1080/09553000701616114, 17852557.
86. Vergis R, Corbishley CM, Norman AR, Bartlett J, Jhavar S, Borre M, Heeboll S, Horwich A, Huddart R, Khoo V, Eeles R, Cooper C, Sydes M, Dearnaley D, Parker C. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol 2008, 9:342-351. 10.1016/S1470-2045(08)70076-7, 18343725.
87. Fuks Z, Kolesnick R. Engaging the vascular component of the tumor response. Cancer Cell 2005, 8:89-91. 10.1016/j.ccr.2005.07.014, 16098459.
88. Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, Cenci T, Maira G, Parati E, Stassi G, Larocca L, De Maria R. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010, 468:824-828. 10.1038/nature09557, 21102434.
89. Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 2010, 120:694-705. 10.1172/JCI40283, 2827954, 20179352.
90. Kamlah F, Hanze J, Arenz A, Seay U, Hasan D, Juricko J, Bischoff B, Gottschald OR, Fournier C, Taucher-Scholz G, Scholz M, Seeger W, Engenhart-Cabillic R, Rose F. Comparison of the effects of carbon ion and photon irradiation on the angiogenic response in human lung adenocarcinoma cells. Int J Radiat Oncol Biol Phys 2011, 80:1541-1549. 10.1016/j.ijrobp.2011.03.033, 21621345.
91. Chen Z, Lu W, Garcia-Prieto C, Huang P. The Warburg effect and its cancer therapeutic implications. Journal of bioenergetics and biomembranes 2007, 39:267-274. 10.1007/s10863-007-9086-x, 17551814.
92. Lopez-Lazaro M. The warburg effect: why and how do cancer cells activate glycolysis in the presence of oxygen?. Anti-cancer agents in medicinal chemistry 2008, 8(3):305-312.
93. Gillies RJ, Gatenby RA. Adaptive landscapes and emergent phenotypes: why do cancers have high glycolysis?. J Bioenerg Biomembr 2007, 39:251-257. 10.1007/s10863-007-9085-y, 17624581.
94. Ganapathy V, Thangaraju M, Prasad PD. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther 2009, 121:29-40.
95. Gogvadze V, Orrenius S, Zhivotovsky B. Mitochondria in cancer cells: what is so special about them?. Trends in Cell Biology 2008, 18:165-173. 10.1016/j.tcb.2008.01.006, 18296052.
96. Sattler U, Hirschhaeuser F, Mueller-Klieser W. Manipulation of glycolysis in malignant tumors: fantasy or therapy?. Current medicinal chemistry 2010, 17:96-108. 10.2174/092986710790112657, 19941476.
97. Estrela J, Ortega A, Obrador E. Glutathione in cancer biology and therapy. Critical reviews in clinical laboratory sciences 2006, 43:143-181. 10.1080/10408360500523878, 16517421.
98. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. Nat Rev Drug Discov 2009, 8:579-591. 10.1038/nrd2803, 19478820.
99. Cook JA, Gius D, Wink DA, Krishna MC, Russo A, Mitchell JB. Oxidative stress, redox, and the tumor microenvironment. Semin Radiat Oncol 2004, 14:259-266. 10.1016/j.semradonc.2004.04.001, 15254869.
100. Colen CB, Seraji-Bozorgzad N, Marples B, Galloway MP, Sloan AE, Mathupala SP. Metabolic remodeling of malignant gliomas for enhanced sensitization during radiotherapy: an in vitro study. Neurosurgery 2006, 59:1313-1323. discussion 1323-1314, 3385862, 17277695.
101. Coleman C, Mitchell J. Clinical radiosensitization: why it does and does not work. Journal of clinical oncology 1999, 17(1):1-3.
102. Tennant DA, Duran RV, Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 2010, 10:267-277. 10.1038/nrc2817, 20300106.
103. Hanot M, Boivin A, Malésys C, Beuve M, Colliaux A, Foray N, Douki T, Ardail D, Rodriguez-Lafrasse C. Glutathione depletion and carbon ion radiation potentiate clustered DNA lesions, cell death and prevent chromosomal changes in cancer cells progeny. PloS one 2012, 7(11):e44367. 10.1371/journal.pone.0044367, 3502420, 23185232.
104. Haro K, Sheth A, Scheinberg D. Dysregulation of IRP1-mediated iron metabolism causes gamma ray-specific radioresistance in leukemia cells. PloS one 2012, 7(11):e48841. 10.1371/journal.pone.0048841, 3498264, 23155415.
105. Letelier M, Sánchez-Jofré S, Peredo-Silva L, Cortés-Troncoso J, Aracena-Parks P. Mechanisms underlying iron and copper ions toxicity in biological systems: Pro-oxidant activity and protein-binding effects. Chemico-biological interactions 2010, 188:220-227.
106. Hentze M, Muckenthaler M, Andrews N. Balancing acts: molecular control of mammalian iron metabolism. Cell 2004, 117(3):285-297. 10.1016/S0092-8674(04)00343-5, 15109490.
107. Rouault T. The role of iron regulatory proteins in mammalian iron homeostasis and disease. Nature chemical biology 2006, 2:406-414. 10.1038/nchembio807, 16850017.
108. Suit H, DeLaney T, Goldberg S, Paganetti H, Clasie B, Gerweck L, Niemierko A, Hall E, Flanz J, Hallman J, Trofimov A. Proton vs carbon ion beams in the definitive radiation treatment of cancer patients. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology 2010, 95:3-22. 10.1016/j.radonc.2010.01.015, 20185186.
109. Wikstrand CJ, McLendon RE, Friedman AH, Bigner DD. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res 1997, 57:4130-4140.
110. McCubrey JA, Lahair MM, Franklin RA. OSU-03012 in the treatment of glioblastoma. Mol Pharmacol 2006, 70:437-439. 10.1124/mol.106.026252, 16675657.
111. Wallner KE, Galicich JH, Krol G, Arbit E, Malkin MG. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 1989, 16:1405-1409. 10.1016/0360-3016(89)90941-3, 2542195.
112. Salcman M. Survival in glioblastoma: historical perspective. Neurosurgery 1980, 7:435-439. 10.1227/00006123-198011000-00001, 6255368.
113. Marks LB, Ten Haken RK, Martel MK. Guest editor's introduction to QUANTEC: a users guide. Int J Radiat Oncol Biol Phys 2010, 76:S1-2. 10.1016/j.ijrobp.2009.08.075, 20171501.
114. Giese A, Westphal M. Glioma invasion in the central nervous system. Neurosurgery 1996, 39:235-250. discussion 250-232, 10.1097/00006123-199608000-00001, 8832660.
115. Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology 1980, 30:907-911. 10.1212/WNL.30.9.907, 6252514.
116. Chugh R, Tawbi H, Lucas DR, Biermann JS, Schuetze SM, Baker LH. Chordoma: the nonsarcoma primary bone tumor. Oncologist 2007, 12:1344-1350. 10.1634/theoncologist.12-11-1344, 18055855.
117. Schulz-Ertner D, Karger CP, Feuerhake A, Nikoghosyan A, Combs SE, Jakel O, Edler L, Scholz M, Debus J. Effectiveness of carbon ion radiotherapy in the treatment of skull-base chordomas. Int J Radiat Oncol Biol Phys 2007, 68:449-457. 10.1016/j.ijrobp.2006.12.059, 17363188.
118. Mizoe JE, Hasegawa A, Takagi R, Bessho H, Onda T, Tsujii H. Carbon ion radiotherapy for skull base chordoma. Skull Base 2009, 19:219-224. 10.1055/s-0028-1114295, 2702197, 19881902.
119. Munzenrider JE, Liebsch NJ. Proton therapy for tumors of the skull base. Strahlenther Onkol 1999, 175(Suppl 2):57-63.
120. Noel G, Habrand JL, Jauffret E, de Crevoisier R, Dederke S, Mammar H, Haie-Meder C, Pontvert D, Hasboun D, Ferrand R, Boisserie G, Beaudre A, Gaboriaud G, Guedea F, Petriz L, Mazeron JJ. Radiation therapy for chordoma and chondrosarcoma of the skull base and the cervical spine. Prognostic factors and patterns of failure. Strahlenther Onkol 2003, 179:241-248. 10.1007/s00066-003-1065-5, 12707713.
121. Igaki H, Tokuuye K, Okumura T, Sugahara S, Kagei K, Hata M, Ohara K, Hashimoto T, Tsuboi K, Takano S, Matsumura A, Akine Y. Clinical results of proton beam therapy for skull base chordoma. Int J Radiat Oncol Biol Phys 2004, 60:1120-1126. 10.1016/j.ijrobp.2004.05.064, 15519783.
122. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Stereotactic body radiotherapy for central lung tumors. J Thorac Oncol 2012, 7:1394-1399. 10.1097/JTO.0b013e3182614bf3, 22843088.
123. Guckenberger M, Kestin LL, Hope AJ, Belderbos J, Werner-Wasik M, Yan D, Sonke JJ, Bissonnette JP, Wilbert J, Xiao Y, Grills IS. Is there a lower limit of pretreatment pulmonary function for safe and effective stereotactic body radiotherapy for early-stage non-small cell lung cancer?. J Thorac Oncol 2012, 7:542-551. 10.1097/JTO.0b013e31824165d7, 22258475.
124. Dunlap NE, Larner JM, Read PW, Kozower BD, Lau CL, Sheng K, Jones DR. Size matters: a comparison of T1 and T2 peripheral non-small-cell lung cancers treated with stereotactic body radiation therapy (SBRT). J Thorac Cardiovasc Surg 2010, 140:583-589. 10.1016/j.jtcvs.2010.01.046, 20478576.
125. Koto M, Takai Y, Ogawa Y, Matsushita H, Takeda K, Takahashi C, Britton KR, Jingu K, Takai K, Mitsuya M, Nemoto K, Yamada S. A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cance. Radiother Oncol 2007, 85:429-434. 10.1016/j.radonc.2007.10.017, 18022720.
126. Guckenberger M, Baier K, Polat B, Richter A, Krieger T, Wilbert J, Mueller G, Flentje M. Dose-response relationship for radiation-induced pneumonitis after pulmonary stereotactic body radiotherapy. Radiother Oncol 2010, 97:65-70. 10.1016/j.radonc.2010.04.027, 20605245.
127. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009, 27:1485-1491. 10.1200/JCO.2008.20.7753, 2668555, 19224838.
128. Levy I, Greig PD, Gallinger S, Langer B, Sherman M. Resection of hepatocellular carcinoma without preoperative tumor biopsy. Ann Surg 2001, 234:206-209. 10.1097/00000658-200108000-00010, 1422007, 11505066.
129. Grazi GL, Ercolani G, Pierangeli F, Del Gaudio M, Cescon M, Cavallari A, Mazziotti A. Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value. Ann Surg 2001, 234:71-78. 10.1097/00000658-200107000-00011, 1421950, 11420485.
130. Komatsu S, Fukumoto T, Demizu Y, Miyawaki D, Terashima K, Sasaki R, Hori Y, Hishikawa Y, Ku Y, Murakami M. Clinical results and risk factors of proton and carbon ion therapy for hepatocellular carcinoma. Cancer 2011, 117:4890-4904. 10.1002/cncr.26134, 21495022.
131. Kato H, Tsujii H, Miyamoto T, Mizoe JE, Kamada T, Tsuji H, Yamada S, Kandatsu S, Yoshikawa K, Obata T, Ezawa H, Morita S, Tomizawa M, Morimoto N, Fujita J, Ohto M. Results of the first prospective study of carbon ion radiotherapy for hepatocellular carcinoma with liver cirrhosis. Int J Radiat Oncol Biol Phys 2004, 59:1468-1476. 10.1016/j.ijrobp.2004.01.032, 15275734.
132. Chiba T, Tokuuye K, Matsuzaki Y, Sugahara S, Chuganji Y, Kagei K, Shoda J, Hata M, Abei M, Igaki H, Tanaka N, Akine Y. Proton beam therapy for hepatocellular carcinoma: a retrospective review of 162 patients. Clin Cancer Res 2005, 11:3799-3805. 10.1158/1078-0432.CCR-04-1350, 15897579.
133. Kawashima M, Furuse J, Nishio T, Konishi M, Ishii H, Kinoshita T, Nagase M, Nihei K, Ogino T. Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma. J Clin Oncol 2005, 23:1839-1846. 10.1200/JCO.2005.00.620, 15774777.
134. Wagner M, Redaelli C, Lietz M, Seiler C, Friess H, Büchler M. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. The British journal of surgery 2004, 91:586-594. 10.1002/bjs.4484, 15122610.
135. Bachmann J, Michalski C, Martignoni M, Büchler M, Friess H. Pancreatic resection for pancreatic cancer. HPB: the official journal of the International Hepato Pancreato Biliary Association 2006, 8:346-351. 10.1080/13651820600803981, 2020746, 18333087.
136. Hong TS, Ryan DP, Blaszkowsky LS, Mamon HJ, Kwak EL, Mino-Kenudson M, Adams J, Yeap B, Winrich B, DeLaney TF, Fernandez-Del Castillo C. Phase I study of preoperative short-course chemoradiation with proton beam therapy and capecitabine for resectable pancreatic ductal adenocarcinoma of the head. Int J Radiat Oncol Biol Phys 2011, 79:151-157. 10.1016/j.ijrobp.2009.10.061, 20421151.
137. Combs SE, Ellerbrock M, Haberer T, Habermehl D, Hoess A, Jakel O, Jensen A, Klemm S, Münter M, Naumann J, Nikoghosyan A, Oertel S, Parodi K, Rieken S, Debus J. Heidelberg Ion Therapy Center (HIT): Initial clinical experience in the first 80 patients. Acta Oncol 2010, 49:1132-1140. 10.3109/0284186X.2010.498432, 20831505.
138. Senapati A, O'Leary DP, Flashman KG, Parvaiz A, Thompson MR. Low rates of local recurrence after surgical resection of rectal cancer suggest a selective policy for preoperative radiotherapy. Colorectal Dis 2012, 14:838-843. 10.1111/j.1463-1318.2011.02827.x, 21920008.
139. Combs SE, Kieser M, Habermehl D, Weitz J, Jager D, Fossati P, Orrechia R, Engenhart-Cabillic R, Potter R, Dosanjh M, Jakel O, Buchler MW, Debus J. Phase I/II trial evaluating carbon ion radiotherapy for the treatment of recurrent rectal cancer: the PANDORA-01 trial. BMC Cancer 2012, 12:137. 10.1186/1471-2407-12-137, 3342902, 22472035.
140. Okada T, Kamada T, Tsuji H, Mizoe JE, Baba M, Kato S, Yamada S, Sugahara S, Yasuda S, Yamamoto N, Imai R, Hasegawa A, Imada H, Kiyohara H, Jingu K, Shinoto M, Tsujii H. Carbon ion radiotherapy: clinical experiences at National Institute of Radiological Science (NIRS). J Radiat Res 2010, 51:355-364. 10.1269/jrr.10016, 20508375.
141. Iseli TA, Karnell LH, Graham SM, Funk GF, Buatti JM, Gupta AK, Robinson RA, Hoffman HT. Role of radiotherapy in adenoid cystic carcinoma of the head and neck. J Laryngol Otol 2009, 123:1137-1144. 10.1017/S0022215109990338, 19573256.
142. Mendenhall WM, Morris CG, Amdur RJ, Werning JW, Hinerman RW, Villaret DB. Radiotherapy alone or combined with surgery for adenoid cystic carcinoma of the head and neck. Head Neck 2004, 26:154-162. 10.1002/hed.10380, 14762884.
143. O'Sullivan B, Davis AM, Turcotte R, Bell R, Catton C, Chabot P, Wunder J, Kandel R, Goddard K, Sadura A, Pater J, Zee B. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet 2002, 359:2235-2241. 10.1016/S0140-6736(02)09292-9, 12103287.
144. O'Sullivan B, Griffin AM, Dickie CI, Sharpe MB, Chung PW, Catton CN, Ferguson PC, Wunder JS, Deheshi BM, White LM, Kandel RA, Jaffray DA, Bell RS. Phase 2 study of preoperative image-guided intensity-modulated radiation therapy to reduce wound and combined modality morbidities in lower extremity soft tissue sarcoma. Cancer 2013, 119:1878-1884. 10.1002/cncr.27951, 23423841.
145. Willers H, Hug EB, Spiro IJ, Efird JT, Rosenberg AE, Wang CC. Adult soft tissue sarcomas of the head and neck treated by radiation and surgery or radiation alone: patterns of failure and prognostic factors. Int J Radiat Oncol Biol Phys 1995, 33:585-593. 10.1016/0360-3016(95)00256-X, 7558947.
146. Mendenhall WM, Mendenhall CM, Werning JW, Riggs CE, Mendenhall NP. Adult head and neck soft tissue sarcomas. Head Neck 2005, 27:916-922. 10.1002/hed.20249, 16136585.
147. Barker JL, Paulino AC, Feeney S, McCulloch T, Hoffman H. Locoregional treatment for adult soft tissue sarcomas of the head and neck: an institutional review. Cancer J 2003, 9:49-57. 10.1097/00130404-200301000-00009, 12602768.
148. Hug EB, Loredo LN, Slater JD, DeVries A, Grove RI, Schaefer RA, Rosenberg AE, Slater JM. Proton radiation therapy for chordomas and chondrosarcomas of the skull base. J Neurosurg 1999, 91:432-439. 10.3171/jns.1999.91.3.0432, 10470818.
149. Miyamoto T, Baba M, Yamamoto N, Koto M, Sugawara T, Yashiro T, Kadono K, Ezawa H, Tsujii H, Mizoe JE, Yoshikawa K, Kandatsu S, Fujisawa T. Curative treatment of Stage I non-small-cell lung cancer with carbon ion beams using a hypofractionated regimen. Int J Radiat Oncol Biol Phys 2007, 67:750-758. 10.1016/j.ijrobp.2006.10.006, 17293232.
150. Buijs M, Vossen JA, Frangakis C, Hong K, Georgiades CS, Chen Y, Liapi E, Geschwind JF. Nonresectable hepatocellular carcinoma: long-term toxicity in patients treated with transarterial chemoembolization-single-center experience. Radiology 2008, 249:346-354. 10.1148/radiol.2483071902, 18796686.
151. Cohen SJ, Dobelbower R, Lipsitz S, Catalano PJ, Sischy B, Smith TJ, Haller DG. A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. Int J Radiat Oncol Biol Phys 2005, 62:1345-1350. 10.1016/j.ijrobp.2004.12.074, 16029791.
152. Shinoto M, Yamada S, Yasuda S, Imada H, Shioyama Y, Honda H, Kamada T, Tsujii H, Saisho H. Phase 1 trial of preoperative, short-course carbon-ion radiotherapy for patients with resectable pancreatic cancer. Cancer 2013, 119:45-51. 10.1002/cncr.27723, 22744973.
153. Koong AC, Christofferson E, Le QT, Goodman KA, Ho A, Kuo T, Ford JM, Fisher GA, Greco R, Norton J, Yang GP. Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2005, 63:320-323. 10.1016/j.ijrobp.2005.07.002, 16168826.
154. Akakura K, Tsujii H, Morita S, Tsuji H, Yagishita T, Isaka S, Ito H, Akaza H, Hata M, Fujime M, Harada M, Shimazaki J. Phase I/II clinical trials of carbon ion therapy for prostate cancer. Prostate 2004, 58:252-258. 10.1002/pros.10328, 14743464.
155. Ishikawa H, Tsuji H, Kamada T, Akakura K, Suzuki H, Shimazaki J, Tsujii H. Carbon-ion radiation therapy for prostate cancer. Int J Urol 2012, 19:296-305. 10.1111/j.1442-2042.2012.02961.x, 22320843.
156. Coote JH, Wylie JP, Cowan RA, Logue JP, Swindell R, Livsey JE. Hypofractionated intensity-modulated radiotherapy for carcinoma of the prostate: analysis of toxicity. Int J Radiat Oncol Biol Phys 2009, 74:1121-1127. 10.1016/j.ijrobp.2008.09.032, 19131179.
157. Ishikawa H, Tsuji H, Kamada T, Yanagi T, Mizoe JE, Kanai T, Morita S, Wakatsuki M, Shimazaki J, Tsujii H. Carbon ion radiation therapy for prostate cancer: results of a prospective phase II study. Radiother Oncol 2006, 81:57-64. 10.1016/j.radonc.2006.08.015, 16971008.
158. Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 2007, 68:1424-1430. 10.1016/j.ijrobp.2007.01.067, 17544601.
159. Martin JM, Rosewall T, Bayley A, Bristow R, Chung P, Crook J, Gospodarowicz M, McLean M, Menard C, Milosevic M, Warde P, Catton C. Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 2007, 69:1084-1089. 10.1016/j.ijrobp.2007.04.049, 17606331.
160. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R,. German Rectal Cancer Study Group Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004, 351:1731-1740. 10.1056/NEJMoa040694, 15496622, German Rectal Cancer Study Group.
161. Lybeert ML, Martijn H, De Neve W, Crommelin MA, Ribot JG. Radiotherapy for locoregional relapses of rectal carcinoma after initial radical surgery: definite but limited influence on relapse-free survival and survival. Int J Radiat Oncol Biol Phys 1992, 24:241-246. 10.1016/0360-3016(92)90678-B, 1526862.
162. O'Connell MJ, Childs DS, Moertel CG, Holbrook MA, Schutt AJ, Rubin J, Ritts RE. A prospective controlled evaluation of combined pelvic radiotherapy and methanol extraction residue of BCG (MER) for locally unresectable or recurrent rectal carcinoma. Int J Radiat Oncol Biol Phys 1982, 8:1115-1119. 10.1016/0360-3016(82)90057-8, 6181041.
163. Duenas-Gonzalez A, Zarba JJ, Patel F, Alcedo JC, Beslija S, Casanova L, Pattaranutaporn P, Hameed S, Blair JM, Barraclough H, Orlando M. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol 2011, 29:1678-1685. 10.1200/JCO.2009.25.9663, 21444871.
164. Matsushita K, Ochiai T, Shimada H, Kato S, Ohno T, Nikaido T, Yamada S, Okazumi S, Matsubara H, Takayama W, Ishikura H, Tsujii H. The effects of carbon ion irradiation revealed by excised perforated intestines as a late morbidity for uterine cancer treatment. Surg Today 2006, 36:692-700. 10.1007/s00595-006-3231-8, 16865512.
165. Kato S, Ohno T, Tsujii H, Nakano T, Mizoe JE, Kamada T, Miyamoto T, Tsuji H, Kato H, Yamada S, Kandatsu S, Yoshikawa K, Ezawa H, Suzuki M,. Working Group of the Gynecological Tumor Dose escalation study of carbon ion radiotherapy for locally advanced carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 2006, 65:388-397. 10.1016/j.ijrobp.2005.12.050, 16626894, Working Group of the Gynecological Tumor.
166. Nishida Y, Kamada T, Imai R, Tsukushi S, Yamada Y, Sugiura H, Shido Y, Wasa J, Ishiguro N. Clinical outcome of sacral chordoma with carbon ion radiotherapy compared with surgery. Int J Radiat Oncol Biol Phys 2011, 79:110-116. 10.1016/j.ijrobp.2009.10.051, 20400242.
167. Imai R, Kamada T, Sugahara S, Tsuji H, Tsujii H. Carbon ion radiotherapy for sacral chordoma. Br J Radiol 2011, 84(Spec No 1):S48-54. 3473887, 21427182.
168. Imai R, Kamada T, Tsuji H, Sugawara S, Serizawa I, Tsujii H, Tatezaki S. Effect of carbon ion radiotherapy for sacral chordoma: results of Phase I-II and Phase II clinical trials. Int J Radiat Oncol Biol Phys 2010, 77:1470-1476. 10.1016/j.ijrobp.2009.06.048, 19939576.
169. Ohno T. Particle radiotherapy with carbon ion beams. EPMA J 2013, 4:9. 10.1186/1878-5085-4-9, 3598788, 23497542.
170. Kosaki K, Ecker S, Habermehl D, Rieken S, Jakel O, Herfarth K, Debus J, Combs SE. Comparison of intensity modulated radiotherapy (IMRT) with intensity modulated particle therapy (IMPT) using fixed beams or an ion gantry for the treatment of patients with skull base meningiomas. Radiat Oncol 2012, 7:44. 10.1186/1748-717X-7-44, 3338385, 22439607.
171. Habermehl D, Debus J, Ganten T, Ganten MK, Bauer J, Brecht IC, Brons S, Haberer T, Haertig M, Jakel O, Parodi K, Welzel T, Combs SE. Hypofractionated carbon ion therapy delivered with scanned ion beams for patients with hepatocellular carcinoma - feasibility and clinical response. Radiat Oncol 2013, 8:59. 10.1186/1748-717X-8-59, 3663740, 23497349.
172. Skinner HD, Hong TS, Krishnan S. Charged-particle therapy for hepatocellular carcinoma. Semin Radiat Oncol 2011, 21:278-286. 10.1016/j.semradonc.2011.05.007, 3230301, 21939857.